Mesenchymal Stromal Cell Therapy for Acute Graft-Versus-Host Disease: Timing, Disease Context, and Biomarkers as Determinants of Clinical Response

Abstract Purpose of Review Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for hematological malignancies and inherited disorders. However, graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality. Mesenchymal stromal cells (MSCs) have emerged as a cellular therapy because of their immunomodulatory and tissue-repair properties, although clinical responses have been inconsistent. This review examines evidence supporting MSC use for GVHD, focusing on treatment timing, disease stage and severity, patient characteristics, MSC product properties, and biomarkers predicting response. Recent Findings MSCs modulate innate and adaptive immunity, including T cells, B cells, natural killer cells, dendritic cells, and macrophages, through paracrine mediators, extracellular vesicles, and cell-cell interactions. Clinical studies have reported activity in GVHD prophylaxis and treatment, particularly in selected patients with steroid-refractory acute GVHD (SR-aGVHD), whereas randomized studies have not consistently demonstrated benefit across unselected populations. The clinical development of remestemcel-L provided important translational evidence, culminating in FDA approval of remestemcel-L-rknd (Ryoncil) in December 2024 for pediatric patients aged 2 months and older with SR-aGVHD, the first FDA-approved MSC-based therapy for GVHD. Biomarkers including ST2, REG3α, elafin, CXCL10, IL-7, FGFR1, and immune-cell phenotypes may aid risk stratification and treatment monitoring. Summary Evidence supports a context-dependent model of MSC efficacy rather than a uniform therapeutic effect. Clinical activity may depend on disease stage, inflammatory burden, patient characteristics, MSC source and quality, dosing, and timing. Future studies should clarify which patients benefit, when treatment should be administered, and which cellular or molecular characteristics predict response.

Authors

Institutions

Publication Details

Journal
Current Stem Cell Reports
Published
2026-11-13
DOI
https://doi.org/10.1007/s40778-026-00265-6
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mesenchymal Stromal Cell Therapy for Acute Graft-Versus-Host Disease: Timing, Disease Context, and Biomarkers as Determinants of Clinical Response

Rosana Lopes Rodrigues Amon, Ricardo Ambrósio Fock, Beatriz Thiago Ferreira de Almeida, Ana Clara Paes Assis Santos
Current Stem Cell Reports
Hematopoietic Stem Cell Transplantation
article

Mesenchymal Stromal Cell Therapy for Acute Graft-Versus-Host Disease: Timing, Disease Context, and Biomarkers as Determinants of Clinical Response

Rosana Lopes Rodrigues Amon, Ricardo Ambrósio Fock, Beatriz Thiago Ferreira de Almeida, Ana Clara Paes Assis Santos
article en

Abstract

Abstract Purpose of Review Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for hematological malignancies and inherited disorders. However, graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality. Mesenchymal stromal cells (MSCs) have emerged as a cellular therapy because of their immunomodulatory and tissue-repair properties, although clinical responses have been inconsistent. This review examines evidence supporting MSC use for GVHD, focusing on treatment timing, disease stage and severity, patient characteristics, MSC product properties, and biomarkers predicting response. Recent Findings MSCs modulate innate and adaptive immunity, including T cells, B cells, natural killer cells, dendritic cells, and macrophages, through paracrine mediators, extracellular vesicles, and cell-cell interactions. Clinical studies have reported activity in GVHD prophylaxis and treatment, particularly in selected patients with steroid-refractory acute GVHD (SR-aGVHD), whereas randomized studies have not consistently demonstrated benefit across unselected populations. The clinical development of remestemcel-L provided important translational evidence, culminating in FDA approval of remestemcel-L-rknd (Ryoncil) in December 2024 for pediatric patients aged 2 months and older with SR-aGVHD, the first FDA-approved MSC-based therapy for GVHD. Biomarkers including ST2, REG3α, elafin, CXCL10, IL-7, FGFR1, and immune-cell phenotypes may aid risk stratification and treatment monitoring. Summary Evidence supports a context-dependent model of MSC efficacy rather than a uniform therapeutic effect. Clinical activity may depend on disease stage, inflammatory burden, patient characteristics, MSC source and quality, dosing, and timing. Future studies should clarify which patients benefit, when treatment should be administered, and which cellular or molecular characteristics predict response.

Current Stem Cell ReportsVol. 12(1)
Universidade de São Paulo (BR)
Universidade de São Paulo
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon